Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $113.28 USD
Change Today +1.06 / 0.94%
Volume 200.0
MKGAF On Other Exchanges
As of 8:10 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

merck kgaa (MKGAF) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/23/15 - $114.31
52 Week Low
04/16/14 - $79.01
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for MERCK KGAA (MKGAF)

Related News

No related news articles were found.

merck kgaa (MKGAF) Related Businessweek News

No Related Businessweek News Found

merck kgaa (MKGAF) Details

Merck Kommanditgesellschaft auf Aktien discovers, develops, manufactures, and markets pharmaceutical and chemical products worldwide. The company provides pharmaceutical and biological prescription drugs to treat cancer, multiple sclerosis, infertility, growth disorders, and cardiovascular and metabolic diseases; fertility drugs for every stage of the reproductive cycle; hypoallergenic products for specific immunotherapy and diagnosis of type 1 allergies; and biosimilars focusing on oncology and inflammatory disorders. It also manufactures and markets over-the-counter pharmaceuticals to address mobility, women’s and children’s health, cough and cold, and everyday health protection under the Neurobion, Bion, Seven Seas, Nasivin, Femibion, Dolo-Neurobion, Floratil, Sangobion, Vigantoletten, Apaisyl, and Kytta brand names. In addition, the company offers life science tools and technologies for use in the research, development, and manufacture of biotechnological and pharmaceutical drug therapies, as well as in research and application laboratories. Further, it provides specialty chemicals that are used in various end products, including liquid crystals for displays; LED materials for lighting, as well as organic light-emitting diode materials for lighting and displays; functional materials for solar panels and energy solutions; effect pigments, as well as active ingredients and fillers for cosmetics, food, and pharmaceutical products; pigments and functional materials for coatings, printing, and plastics; and specialty chemical materials for the electronics industry. The company has a strategic alliance with Pfizer Inc. to develop and commercialize active ingredients in immuno-oncology; and strategic immuno-oncology collaboration with MorphoSys to discover and develop therapeutic antibodies against immune checkpoints. Merck Kommanditgesellschaft auf Aktien was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA is a subsidiary of E. Merck KG.

39,639 Employees
Last Reported Date: 03/3/15
Founded in 1668

merck kgaa (MKGAF) Top Compensated Officers

Chairman of Executive Board and Chief Executi...
Total Annual Compensation: €6.6M
Group Chief Financial Officer and Member of E...
Total Annual Compensation: €1.2M
Chief Executive Officer of Life Science & Per...
Total Annual Compensation: €4.7M
Vice Chairman of Executive Board and Deputy C...
Total Annual Compensation: €6.0M
Head of Group Human Resources, General Partne...
Total Annual Compensation: €4.0M
Compensation as of Fiscal Year 2014.

merck kgaa (MKGAF) Key Developments

Merck KGaA to Promote Deputy Head Stefan Oschmann to CEO in September 2016

Merck KGaA to appoint its deputy chief, Stefan Oschmann, as CEO in 2016. Oschmann will step into the role of chief executive officer by September next year, replacing Karl-Ludwig Kley, whose contract runs out.

Merck KGaA Announces Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

Merck KGaA announced earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported earnings per share of EUR 0.64 compared to EUR 0.65 per share a year ago. For the year, the company reported net income of EUR 1.16 billion, or EUR 2.66 per share, compared to EUR 1.20 billion, or EUR 2.77 per share, for the year ended December 31, 2013.

Merck Eyes Acquisitions

Merck KGaA (DB:MRK) is looking for acquisition opportunities. Merck is interested in more acquisitions, but the main focus now is on debt reduction, Karl-Ludwig Kley, Chief Executive Officer of Merck told local business magazine Euro am Sonntag in an interview published on March 14, 2015. Merck could still make smaller acquisitions in some areas following the agreed $17-billion takeover of St. Louis-based chemical firm Sigma-Aldrich and the $2.6-billion purchase of AZ Electronic last year, according to Kley. "With these acquisitions we have laid the foundation for profitable growth. We want now to realise this potential," Kley was quoted as saying.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MKGAF:US $113.28 USD +1.06

MKGAF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Koninklijke DSM NV €51.87 EUR +0.43
PPG Industries Inc $222.96 USD +1.66
Seiko Epson Corp ¥2,270 JPY -52.50
Solvay SA €134.00 EUR +0.95
Sherwin-Williams Co/The $281.68 USD +2.36
View Industry Companies

Industry Analysis


Industry Average

Valuation MKGAF Industry Range
Price/Earnings 35.0x
Price/Sales 3.5x
Price/Book 3.4x
Price/Cash Flow 10.4x
TEV/Sales 0.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MERCK KGAA, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at